Ascentage Pharma Group International (NASDAQ:AAPG) Trading Down 4.6% – What’s Next?

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) fell 4.6% during mid-day trading on Monday . The stock traded as low as $16.88 and last traded at $16.6120. 4,994 shares traded hands during mid-day trading, a decline of 27% from the average session volume of 6,831 shares. The stock had previously closed at $17.42.

Analysts Set New Price Targets

A number of equities analysts recently commented on AAPG shares. Deutsche Bank Aktiengesellschaft assumed coverage on Ascentage Pharma Group International in a research note on Friday, April 24th. They issued a “buy” rating and a $40.00 price objective on the stock. B. Riley Financial began coverage on shares of Ascentage Pharma Group International in a report on Wednesday, June 10th. They set a “buy” rating and a $45.00 price target for the company. Raymond James Financial restated a “buy” rating on shares of Ascentage Pharma Group International in a research report on Wednesday, June 10th. Finally, BTIG Research reaffirmed a “buy” rating and issued a $48.00 price objective on shares of Ascentage Pharma Group International in a research note on Monday, June 15th. Two research analysts have rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $46.43.

Ascentage Pharma Group International Price Performance

The company has a debt-to-equity ratio of 0.57, a current ratio of 1.79 and a quick ratio of 1.77. The business has a 50-day moving average of $18.24 and a 200 day moving average of $21.88.

Institutional Investors Weigh In On Ascentage Pharma Group International

A number of hedge funds have recently modified their holdings of AAPG. Citadel Advisors LLC bought a new stake in Ascentage Pharma Group International in the 3rd quarter valued at about $383,000. UBS Group AG increased its stake in shares of Ascentage Pharma Group International by 149.4% in the third quarter. UBS Group AG now owns 18,345 shares of the company’s stock worth $716,000 after purchasing an additional 10,988 shares in the last quarter. Finally, Hsbc Holdings PLC bought a new stake in shares of Ascentage Pharma Group International in the second quarter valued at approximately $391,000.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.